Diagnostic Value of Serum FGF22 and CXCL16 Levels in Patients with Parkinson's Disease for Cognitive Impairment
10.3969/j.issn.1671-7414.2024.03.026
- VernacularTitle:帕金森病患者血清FGF22和CXCL16水平检测对认知障碍的诊断价值
- Author:
Rongrong NIU
1
;
Shixiong SONG
;
Lei SONG
Author Information
1. 邯郸市中医院脑病一科河北邯郸 056000
- Keywords:
fibroblast growth factor 22;
CXC chemokine ligand 16;
Parkinson's disease;
cognitive impairment
- From:
Journal of Modern Laboratory Medicine
2024;39(3):152-156,193
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the diagnostic value of serum levels of fibroblast growth factor 22(FGF22)and CXC chemokine ligand 16(CXCL16)in patients with Parkinson's disease(PD)in cognitive impairment.Methods A total of 125 PD patients admitted to Handan Traditional Chinese Medicine Hospital from June 2022 to June 2023 were selected as the research subjects,and they were separated into a non cognitive impairment group(n=38)and a cognitive impairment group(n=87)based on whether they had cognitive impairment.Enzyme-linked immunosorbent assay(ELISA)was applied to determine the levels of serum FGF22 and CXCL16 in each group.Spearman correlation was applied to analyze the correlation among serum FGF22 and CXCL16 expression levels,Unified Parkinson's Disease Rating Scale(UPDRS)and Montreal Cognitive Assessment(MoCA)scores.Multivariate logistic regression was applied to analyze the factors affecting cognitive impairment in PD patients.Receiver operating characteristic(ROC)curve was applied to analyze the diagnostic efficacy of FGF22 and CXCL16 for cognitive impairment in PD patients.Results Compared with the non cognitive impairment group,the expression level of serum FGF22(184.16±14.62ng/ml vs 203.24±12.15ng/ml)in cognitive impairment group and the MoCA score(23.91±3.14 分 vs 26.54±2.31 分)were decreased(t=7.048,4.460,all P＜0.05),while the expression levels of CXCL16(2.59±0.46ng/ml vs 2.06±0.34ng/ml)and the UPDRS score(41.43±5.62 score vs 32.46±4.28 score)were increased(t=6.376,8.782,all P＜0.05),and the differences were statisaically significant.According to Spearman correlation analysis,the expression level of serum FGF22 was negatively correlated with UPDRS score(r=-0.435,P＜0.05),but positively correlated with MoCA score(r=0.742,P＜0.05).The expression level of CXCL16 in serum was positively correlated with UPDRS score(r=0.532,P＜0.05),but negatively correlated with MoCA score(r=-0.623,P＜0.05).Multivariate logistic analysis showed that FGF22 and MoCA scores were protective factors for cognitive impairment in PD patients(all P＜0.05),while CXCL16 and UPDRS scores were risk factors for cognitive impairment in PD patients(all P＜0.05).The combination of serum FGF22 and CXCL16 in the diagnosis of cognitive impairment in PD patients had better AUC than their respective alone diagnoses(Z=2.919,2.437,P=0.003,0.015),with a sensitivity and a specificity of 93.10％and 73.68％,respectively.Conclusion The levels of serum FGF22 and CXCL16 were closely related to cognitive impairment in PD patients,and the combination of the two could better diagnose whether PD patients have cognitive impairment.
